secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001232524-23-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma reports record 2022 revenue of $3.7B, up 18% YoY; guides 2023 revenue $3.675-3.875B
--------------------------------------------------------------------------------

- Record 2022 total revenue $3.7B (+18% YoY); 2023 revenue guidance $3.675-3.875B (3% growth at midpoint).
- Xywav became largest product in Q4, annualizing >$1B; more narcolepsy patients on Xywav than Xyrem.
- Cash from operations $1.3B in 2022; delevered balance sheet to 2.9x adjusted net leverage.
- Pipeline progress: positive zanidatamab pivotal trial in BTC; Phase 2 suvecaltamide in Parkinson's tremor enrolled.
- FDA approved Rylaze sBLA for MWF IM dosing; Epidyolex launched in all five key EU markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/jazz-20230301.htm
  HTML page:      https://secwatch.observer/filing/0001232524-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer